Perspective Therapeutics (NYSE:CATX) Now Covered by UBS Group

Equities researchers at UBS Group initiated coverage on shares of Perspective Therapeutics (NYSE:CATX - Get Free Report) in a research report issued to clients and investors on Thursday, Marketbeat.com reports. The firm set a "buy" rating and a $20.00 price target on the stock. UBS Group's price objective would indicate a potential upside of 68.21% from the company's current price.

A number of other research firms have also issued reports on CATX. Oppenheimer restated an "outperform" rating and issued a $22.00 price target on shares of Perspective Therapeutics in a research report on Friday, October 11th. Cantor Fitzgerald reissued an "overweight" rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Wedbush assumed coverage on Perspective Therapeutics in a research note on Tuesday, October 1st. They issued an "outperform" rating and a $25.00 target price for the company. Truist Financial initiated coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They set a "buy" rating and a $21.00 price target on the stock. Finally, Bank of America assumed coverage on shares of Perspective Therapeutics in a report on Thursday, July 25th. They issued a "buy" rating and a $24.00 price objective for the company. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Perspective Therapeutics has a consensus rating of "Buy" and a consensus target price of $20.63.

Perspective Therapeutics Stock Up 1.7 %

CATX traded up $0.20 on Thursday, hitting $11.89. 307,057 shares of the company's stock were exchanged, compared to its average volume of 687,263. Perspective Therapeutics has a fifty-two week low of $2.20 and a fifty-two week high of $19.05. The firm's 50-day simple moving average is $13.80.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. The business had revenue of $0.53 million during the quarter. As a group, research analysts anticipate that Perspective Therapeutics will post -0.87 earnings per share for the current year.

Institutional Trading of Perspective Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Perspective Therapeutics by 34.6% during the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company's stock worth $21,158,000 after buying an additional 4,566,356 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Perspective Therapeutics in the 1st quarter worth approximately $15,511,000. Affinity Asset Advisors LLC purchased a new position in shares of Perspective Therapeutics during the 1st quarter worth approximately $6,069,000. Nicholson Wealth Management Group LLC acquired a new stake in Perspective Therapeutics in the 3rd quarter valued at approximately $21,390,000. Finally, Ally Bridge Group NY LLC purchased a new stake in Perspective Therapeutics in the second quarter valued at approximately $3,951,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.